| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $322,142 ) |
| | 2024 | 2024 | SHASQI INC | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44CA265665 | Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma | 000 | 3 | NIH | 3/18/2024 | $322,142 |
| | 2024 | 2023 | SHASQI INC | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44CA285160 | Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry | 001 | 1 | NIH | 1/16/2024 | $781,732 |
| | 2024 | 2023 | SHASQI INC | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44CA285160 | Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry | 000 | 1 | NIH | 1/10/2024 | -$781,732 |
|
| Issue Date FY: 2023 ( Subtotal = $1,080,575 ) |
| | 2023 | 2023 | SHASQI INC | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44CA265665 | Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma | 000 | 2 | NIH | 3/24/2023 | $298,843 |
| | 2023 | 2023 | SHASQI INC | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44CA285160 | Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry | 000 | 1 | NIH | 9/1/2023 | $781,732 |
|
| Issue Date FY: 2022 ( Subtotal = $801,129 ) |
| | 2022 | 2022 | SHASQI, INC. | 665 3RD ST STE 535 | SAN FRANCISCO | CA | 94107-2285 | SAN FRANCISCO | USA | R44CA261573 | Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors | 000 | 2 | NIH | 4/1/2022 | $801,129 |
| | 2022 | 2021 | SHASQI, INC. | 665 3RD ST STE 535 | SAN FRANCISCO | CA | 94107-2285 | SAN FRANCISCO | USA | R44CA265665 | Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma | 000 | 1 | NIH | 9/9/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,575,634 ) |
| | 2021 | 2021 | SHASQI, INC. | 665 3RD ST STE 535 | SAN FRANCISCO | CA | 94107-2285 | SAN FRANCISCO | USA | R44CA261573 | Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors | 001 | 1 | NIH | 8/26/2021 | $0 |
| | 2021 | 2021 | SHASQI, INC. | 665 3RD ST STE 535 | SAN FRANCISCO | CA | 94107-2285 | SAN FRANCISCO | USA | R44CA261573 | Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors | 000 | 1 | NIH | 4/1/2021 | $1,198,848 |
| | 2021 | 2021 | SHASQI, INC. | 665 3RD ST STE 535 | SAN FRANCISCO | CA | 94107-2285 | SAN FRANCISCO | USA | R44CA265665 | Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma | 000 | 1 | NIH | 9/16/2021 | $1,376,786 |
|
|
